Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics

Revista Brasileira de Psiquiatria

Carmen Lúcia Leitão-azevedo²  Lísia Rejane Guimarães²  Martha Guerra Belmonte De Abreu¹  Clarissa Severino Gama¹  Maria Inês Lobato¹  Paulo Silva Belmonte-de-abreu¹ 

[1] ,UFRGS Psychiatry Graduation Program Porto Alegre RS ,Brazil

关键词: Schizophrenia;    Lipids;    Dyslipidemias;    Obesity;    Antipsychotics agents;    Esquizofrenia;    Lipídeos;    Dislipidemias;    Obesidade;    Agentes antipsicóticos;   

DOI  :  10.1590/S1516-44462006005000016

来源: SciELO

【 摘 要 】

OBJECTIVE: First and second generation antipsychotics are associated with metabolic disturbances. A cross-sectional study was designed to follow outpatients at the Schizophrenia and Dementia Program at a major teaching hospital in Porto Alegre, Brazil (Hospital de Clínicas de Porto Alegre) in order to verify whether second generation antipsychotics were associated with higher glucose and lipid levels regardless of age and gender. METHOD: Four metabolic parameters (cholesterol and fractions, glucose and triglycerides) and anthropometric measures were obtained from 124 consecutive adult outpatients diagnosed with schizophrenia by DSM-IV and ICD-10 with the Operational Criteria Checklist for Psychotic Disorders system using the same antipsychotic drug for at least 9 weeks. RESULTS: Most patients had elevated BMI (76.6%) and dyslipidemia (84.7%). Clozapine users had lower HDL levels compared to first generation antipsychotics users. Both groups had elevated body mass index (p = 0.033; OR = 3.3; 95%CI = 1.1-9.8) and second generation antipsychotics (p = 0.021; OR = 3.5; 95%CI = 1.1-11.2) showed significant effect, adjusted for age and gender in the logistic regression for dyslipidemia, and significant age effect for hyperglycemia (p = 0.030; OR = 1.1; 95%CI = 1.0-1.1). DISCUSSION: There was statistically significant association between the use of second generation antipsychotics and dyslipidemia. It raises the issue of increased vulnerability of second generation antipsychotics-treated patients, regardless of age, as well as the need for assertive treatment for overweight and dyslipidemia in schizophrenia in order to reduce the risk of diabetes and cardiovascular disease.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License